What is the share price of Beta Drugs Ltd (BETA) today?

The share price of BETA as on 10th September 2026 is ₹2085.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

What is the return on Beta Drugs Ltd (BETA) share?

The past returns of Beta Drugs Ltd (BETA) share are Past 1 week: -6.27%Past 1 month: -12.11%Past 3 months: 38.76%Past 6 months: 86.15%Past 1 year: 12.73%Past 3 years: 109.80%Past 5 years: 464.52%

What are the peers or stocks similar to Beta Drugs Ltd (BETA)?

The peers or stocks similar to Beta Drugs Ltd (BETA) include: Beta Drugs Ltd Sun Pharmaceutical Industries Ltd Torrent Pharmaceuticals Ltd Cipla Ltd Zydus Lifesciences Ltd Lupin Limited

What is the market cap of Beta Drugs Ltd (BETA) share?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd (BETA) is ₹2580.46 Cr as of 10th September 2026.

What is the 52 week high and low of Beta Drugs Ltd (BETA) share?

The 52-week high of Beta Drugs Ltd (BETA) is ₹2807.90 and the 52-week low is ₹990.10.

What is the PE and PB ratio of Beta Drugs Ltd (BETA) stock?

The P/E (price-to-earnings) ratio of Beta Drugs Ltd (BETA) is 62.19. The P/B (price-to-book) ratio is 13.09.

Which sector does Beta Drugs Ltd (BETA) belong to?

Beta Drugs Ltd (BETA) belongs to the Health Care sector & Pharmaceuticals sub-sector.

How to buy Beta Drugs Ltd (BETA) shares?

You can directly buy Beta Drugs Ltd (BETA) shares on Tickertape. Simply sign up, connect your demat account and place your order.

Beta Drugs Ltd

BETA Share Price

NSE

₹2,085.801.03% (-21.80)

Health Care

Smallcap

With a market cap of ₹2,580 cr, stock is ranked 1,134

High Risk

Stock is 4.18x as volatile as Nifty

BETA Stock Scorecard

Performance

Avg

Price return has been average, nothing exciting

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health Care

Pharmaceuticals Ashish Kacholia Portfolio Top 20 Investors in India Portfolio

Smallcap

With a market cap of ₹2,580 cr, stock is ranked 1,134

High Risk

Stock is 4.18x as volatile as Nifty

BETA Performance & Key Metrics

No LabelNo Label	PB RatioPB Ratio	Dividend YieldDiv. Yield
56.60	13.09	—

Sector PESector PE	Sector PBSector PB	Sector Div YldSctr Div Yld
46.35	5.84	0.49%

BETA Analyst Ratings & Forecast

—

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

BETA Company Profile

Beta Drugs Limited is a pharmaceutical formulation manufacturing company. It is engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Company also engaged manufacturing oncology products

Investor Presentation

View older View older

Jul 27, 2026

PDF

View Older Presentations

BETA Similar Stocks (Peers)

Compare with peers Compare with peers

BETA Similar Stocks (Peers)

Compare with peers Compare with peers

Sun Pharmaceutical Industries Ltd

SUNPHARMA

PE Ratio

39.76

1Y Return

16.10%

Buy Reco %

93.55

Torrent Pharmaceuticals Ltd

TORNTPHARM

PE Ratio

86.09

1Y Return

37.12%

Buy Reco %

82.14

Cipla Ltd

CIPLA

PE Ratio

29.83

1Y Return

12.14%

Buy Reco %

62.86

Zydus Lifesciences Ltd

ZYDUSLIFE

PE Ratio

22.17

1Y Return

7.59%

Buy Reco %

57.69

Lupin Limited

LUPIN

PE Ratio

18.88

1Y Return

4.76%

Buy Reco %

51.52

Compare with Peers

BETA Forecast

BETA Forecasts

BETA

Income

Balance Sheet

Cash Flow

Financial Year		FY 2018		FY 2019		FY 2020		FY 2021		FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	TTM
Total Revenue	50.81	66.30	91.22	116.62	184.60	227.86	297.07	368.80	396.01	419.94
Raw Materials	28.15	37.26	45.21	60.55	96.21	110.40	167.65	175.78	309.15	326.83
Power & Fuel Cost	0.89	1.21	1.95	2.75	3.43	4.79	6.35	7.49
Employee Cost	1.26	3.80	6.95	8.32	12.10	17.08	20.14	26.86
Selling & Administrative Expenses	4.85	7.82	10.27	10.31	16.26	25.89	33.25	47.13
Operating & Other expenses	5.96	4.04	8.52	9.45	13.14	15.83	8.33	35.07
EBITDA	9.70	12.17	18.32	25.24	43.46	53.87	61.35	76.47	86.86	93.11
Depreciation/Amortization	1.85	2.84	3.76	6.87	7.25	10.41	9.78	12.51	17.15	17.78
PBIT	7.85	9.33	14.56	18.37	36.21	43.46	51.57	63.96	69.71	75.33
Interest & Other Items	1.01	1.43	2.59	2.42	1.90	2.41	2.82	6.99	15.31	14.54
PBT	6.84	7.90	11.97	15.95	34.31	41.05	48.75	56.97	54.40	60.79
Taxes & Other Items	0.07	-0.14	2.56	4.23	9.48	10.34	12.32	14.55	12.91	15.20
Net Income	6.77	8.04	9.41	11.72	24.83	30.71	36.43	42.42	41.49	45.59
EPS	7.45	8.85	9.81	11.61	24.60	30.42	36.09	42.02	40.92	45.16
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout ratio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

BETA Income Statement

Quarter		dec 2024		mar 2025		jun 2025		sep 2025	dec 2025	mar 2026	jun 2026
Total Revenue	89.26	97.73	103.19	106.37	89.58	96.86	127.13
Operating & Other expenses	72.18	78.64	80.50	82.08	70.28	76.29	98.18
EBITDA	17.08	19.09	22.69	24.29	19.30	20.57	28.95
Depreciation/Amortization	3.24	3.57	3.73	4.24	4.39	4.80	4.35
PBIT	13.84	15.52	18.96	20.05	14.91	15.77	24.60
Interest & Other Items	1.88	3.29	3.32	3.61	4.43	3.94	2.56
PBT	11.96	12.23	15.64	16.44	10.48	11.83	22.04
Taxes & Other Items	3.01	3.20	3.95	4.23	1.95	2.78	6.24
Net Income	8.95	9.03	11.69	12.21	8.53	9.05	15.80
EPS	9.31	9.40	11.59	12.10	8.40	8.93	14.78

Financial Year		FY 2018		FY 2019		FY 2020		FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Cash from Operating Activities	17.10	0.11	8.41	18.60	29.63	23.38	30.93	36.14
Cash from Investing Activities	-10.79	-20.78	-15.05	-5.85	-21.75	-19.07	-13.97	-35.72
Cash from Financing Activities	5.45	12.07	8.73	-7.71	-0.97	-2.47	-7.49	117.97
Net Change in Cash	+11.76	-8.60	+2.09	+5.04	+6.91	+1.84	+9.47	+118.39
Changes in Working Capital	-4.80	-9.43	-5.97	-3.90	-9.77	-19.69	-13.58	-19.03
Capital Expenditures	8.28	20.67	15.30	5.76	19.43	18.21	11.62	36.86
Free Cash Flow	8.82	-20.56	-6.89	12.84	10.20	5.17	19.31	-0.72

BETA Company Updates

FY 2027FY 2027

Annual Report Pending

Investor Presentation

Jul 27PDF

BETA Stock Peers

BETA Past Performance & Peer Comparison

Comparing 3 stocks from
Health CarePharmaceuticals

Valuation

Technical

Forecast

Compare valuation on Screener

Stock	PE RatioPE Ratio	PB RatioPB Ratio	Div. YieldDividend Yield
Beta Drugs Ltd	62.19	13.09	—
Sun Pharmaceutical Industries Ltd	39.76	5.44	0.84%
Torrent Pharmaceuticals Ltd	86.09	10.59	0.69%
Cipla Ltd	29.83	3.35	0.91%

Stock	Buy Reco %Buy Reco %	Upside %Upside %	1Y Fwd EPS Grwth1Y Forward EPS Growth
Beta Drugs Ltd	Pro
Sun Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd
Cipla Ltd

Stock	VolatilityVolatility	RSI–14DRSI – 14D	Price Mom RankPrice Momentum Rank
Beta Drugs Ltd	55.01%	48.92	Pro
Sun Pharmaceutical Industries Ltd	20.12%	29.06
Torrent Pharmaceuticals Ltd	22.36%	36.55
Cipla Ltd	21.55%	32.18

BETA Stock Price Comparison

Compare BETA with any stock or ETF

BETA

BETA Holdings

BETA Shareholdings

BETA Promoter Holdings Trend

BETA Institutional Holdings Trend

BETA Shareholding Pattern

BETA Shareholding History

Foreign Institutions

BETA Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing BETA stock

Looks like this stock is not in any smallcase yet.

BETA Events

BETA Dividend Trend

Dividends

Corp. Actions

Announcements

Legal Orders

BETA Dividend Trend

BETA Dividends

Hmm, looks like data is unavailable here. Please come back after some time

No upcoming corporate actions are available

Bonus

Ex DateEx DateMar 26, 2025

1:20 Bonus Issue of Equity Shares

1:20 Bonus Issue of Equity Shares | Ratio: 1:20

Ratio

1:20

Ex DateEx Date

Mar 26, 2025

No upcoming announcements are available

Analysts/Institutional Investor Meet/Con. Call Updates

Announced OnSep 10, 2026

Beta Drugs Limited has informed the Exch

Beta Drugs Limited has informed the Exch Download

Link

Download

Announced On

Sep 10, 2026

Copy of Newspaper Publication

Announced OnSep 7, 2026

Beta Drugs Limited has informed the Exch

Beta Drugs Limited has informed the Exch Download

Link

Download

Announced On

Sep 7, 2026

Shareholders meeting

Announced OnSep 5, 2026

Beta Drugs Limited has informed the Exch

Beta Drugs Limited has informed the Exch Download

Link

Download

Announced On

Sep 5, 2026

General Updates

Announced OnSep 3, 2026

Beta Drugs Limited has informed the Exch

Beta Drugs Limited has informed the Exch Download

Link

Download

Announced On

Sep 3, 2026

Shareholders meeting

Announced OnSep 3, 2026

Beta Drugs Limited has informed the Exch

Beta Drugs Limited has informed the Exch Download

Link

Download

Announced On

Sep 3, 2026

BETA Legal Orders

Hmm, looks like data is unavailable here. Please come back after some time

BETA Stock News & Opinions

Earnings

Beta Drugs consolidated net profit rises 35.04% in the June 2026 quarter

Net profit of Beta Drugs rose 35.04% to Rs 15.80 crore in the quarter ended June 2026 as against Rs 11.70 crore during the previous quarter ended June 2025. Sales rose 25.29% to Rs 125.55 crore in the quarter ended June 2026 as against Rs 100.21 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales125.55100.21 25 OPM %21.8019.66 - PBDT26.3919.37 36 PBT22.0415.65 41 NP15.8011.70 35 Powered by Capital Market - Live

1 month agoCapital Market - Live

Earnings

Beta Drugs standalone net profit rises 40.19% in the June 2026 quarter

Net profit of Beta Drugs rose 40.19% to Rs 5.93 crore in the quarter ended June 2026 as against Rs 4.23 crore during the previous quarter ended June 2025. Sales declined 15.82% to Rs 55.83 crore in the quarter ended June 2026 as against Rs 66.32 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales55.8366.32 -16 OPM %18.1811.32 - PBDT10.427.69 36 PBT7.935.65 40 NP5.934.23 40 Powered by Capital Market - Live

1 month agoCapital Market - Live

Corporate

Beta Drugs to hold board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 20 July 2026.

1 month agoCapital Market - Live

Earnings

Beta Drugs consolidated net profit rises 0.22% in the March 2026 quarter

Net profit of Beta Drugs rose 0.22% to Rs 9.05 crore in the quarter ended March 2026 as against Rs 9.03 crore during the previous quarter ended March 2025. Sales rose 0.21% to Rs 93.96 crore in the quarter ended March 2026 as against Rs 93.76 crore during the previous quarter ended March 2025. For the full year,net profit declined 2.22% to Rs 41.48 crore in the year ended March 2026 as against Rs 42.42 crore during the previous year ended March 2025. Sales rose 6.20% to Rs 384.83 crore in the year ended March 2026 as against Rs 362.36 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales93.9693.76 0 384.83362.36 6 OPM %18.8218.50 -19.6720.59 - PBDT16.6318.02 -8 71.5574.05 -3 PBT11.8314.45 -18 54.3961.54 -12 NP9.059.03 0 41.4842.42 -2 Powered by Capital Market - Live

3 months agoCapital Market - Live

Corporate

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 14 May 2026.

3 months agoCapital Market - Live

Earnings

Beta Drugs consolidated net profit declines 4.80% in the December 2025 quarter

Net profit of Beta Drugs declined 4.80% to Rs 8.52 crore in the quarter ended December 2025 as against Rs 8.95 crore during the previous quarter ended December 2024. Sales declined 1.16% to Rs 87.27 crore in the quarter ended December 2025 as against Rs 88.29 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales87.2788.29 -1 OPM %19.4720.90 - PBDT14.8617.55 -15 PBT10.4714.31 -27 NP8.528.95 -5 Powered by Capital Market - Live

6 months agoCapital Market - Live

Corporate

Beta Drugs schedules EGM

Beta Drugs announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 February 2026.Powered by Capital Market - Live

7 months agoCapital Market - Live

Corporate

Beta Drugs to conduct board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 9 January 2026.Powered by Capital Market - Live

8 months agoCapital Market - Live

Corporate

Beta Drugs to convene board meeting

Beta Drugs will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

10 months agoCapital Market - Live

Corporate

Beta Drugs to hold AGM

Beta Drugs announced that the 20th Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live

1 year agoCapital Market - Live

Frequently asked questions

What is the share price of Beta Drugs Ltd (BETA) today?
The share price of BETA as on 10th September 2026 is ₹2085.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.
What is the return on Beta Drugs Ltd (BETA) share?
The past returns of Beta Drugs Ltd (BETA) share are
- Past 1 week: -6.27%
- Past 1 month: -12.11%
- Past 3 months: 38.76%
- Past 6 months: 86.15%
- Past 1 year: 12.73%
- Past 3 years: 109.80%
- Past 5 years: 464.52%
What are the peers or stocks similar to Beta Drugs Ltd (BETA)?
The peers or stocks similar to Beta Drugs Ltd (BETA) include:
What is the market cap of Beta Drugs Ltd (BETA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd (BETA) is ₹2580.46 Cr as of 10th September 2026.
What is the 52 week high and low of Beta Drugs Ltd (BETA) share?
The 52-week high of Beta Drugs Ltd (BETA) is ₹2807.90 and the 52-week low is ₹990.10.
What is the PE and PB ratio of Beta Drugs Ltd (BETA) stock?
The P/E (price-to-earnings) ratio of Beta Drugs Ltd (BETA) is 62.19. The P/B (price-to-book) ratio is 13.09.
Which sector does Beta Drugs Ltd (BETA) belong to?
Beta Drugs Ltd (BETA) belongs to the Health Care sector & Pharmaceuticals sub-sector.
How to buy Beta Drugs Ltd (BETA) shares?
You can directly buy Beta Drugs Ltd (BETA) shares on Tickertape. Simply sign up, connect your demat account and place your order.